Research Article
Low-Dose Aspirin as Primary Prophylaxis for Cardiovascular Events in Rheumatoid Arthritis: An Italian Multicentre Retrospective Study
Table 1
Baseline features and treatment during follow-up of the overall cohort.
| | Baseline features |
| | Sex: F/M ratio (%) | 633/113 (84.8%) | | Age (years) | | | Median (IQR) | 60.9 (52–68.6) | | Mean ± SD | 59.5 ± 13 | | Disease duration, years from onset | | | Median (IQR) | 11.9 (7.37–18) | | RF+/−, (%) | 436/304 (58.9%) | | ACPA+/−, (%) | 371/349 (52%) | | Erosion+/−, (%) | 429/282 (60%) | | SDAI baseline | | | Median (IQR) | 14 (7.2–22.9) | | HAQ-DI baseline | | | Median (IQR) | 1 (0.5–1.5) | | Smoke+/−, (%) | 325/397 (45%) | | Hypertension+/−, (%) | 367/379 (49%) | | Diabetes+/−, (%) | 96/650 (13%) | | Hypercholesterolemia+/−, (%) | 276/449 (38%) | | Obesity+/−, (%) | 112/631 (15%) |
| | Treatment during follow-up |
| | Anti-TNF, (%) | 393/353 (52.6%) | | Mean duration (years) | 5.23 | | Non-anti-TNF-bDMARDs, (%) | 209/536 (28%) | | Mean duration (years) | 3.68 | | MTX+/−, (%) | 649/97 (87%) | | Mean duration (years) | 6.16 | Other csDMARDs+/−, (%)
Mean duration (years) | Leflunomide 182/564 (24.4%); yrs 4.06
Sulfasalazine 127/617 (17%); yrs 2.8
Hydroxychloroquine 288/458 (38.6%); yrs 4.25 | | Low-dose steroids (2.5–5 mg), (%) | 651/95 (87.2%) | | Mean duration (years)+ | 6.88 | | Cumulative dose of steroids (g) | | | Mean ± SD | 1.08 ± 1.07 | | Statin+/−, (%) | 149/494 (19.2%) | | Mean duration (years) | 5.15 |
|
|
IQR: interquartile range; SD: standard deviation; RF: rheumatoid factor; ACPA: anti-citrullinated cyclic peptide antibodies; SDAI: Simplified Disease Activity Index; HAQ-DI: Health Assessment Questionnaire-Disability Index; TNF: tumor necrosis factor; csDMARDs: conventional synthetic disease-modifying antirheumatic drugs; bDMARDs: biological disease-modifying antirheumatic drugs; MTX: methotrexate; ASA: acetylsalicylic acid.
|
